SuperHuman-2.0 VHH Antibody Library for Antibody Development

Don’t waste time in translation or dealing with poor attributes. The SuperHuman therapeutic-ready monoclonal antibody library rapidly delivers human antibody hits that are unparalleled in their developability.

Watch this video to see how a client first panned yeast display, then phage display, and finally mice models with no promising results. The client eventually found success with the SuperHuman library.

 

Use this VHH antibody library and antibody discovery platform to:

  • Identify hits with unprecedented speed

    Rapidly discover unique antibodies against any target of interest with this antibody library screening phage display technology.

    The SuperHuman antibody library screening technology delivers more monoclonal antibody hits in less lead discovery and development time than hybridoma, traditional phage and transgenic methods. Charles River offers this antibody discovery platform to discover humanized VHH antibodies against any target of interest including GPCRs.This Distributed Bio technology offers advantages over panned yeast display, then phage display, and mice models.

  • Ensure more hits through diversity

    The SuperHuman library is over 100x more diverse than any previous  human antibody library. This unprecedented diversity has resulted in a unique engineering opportunity: a library that generates over 300 unique hits against every one of the antigens in the pipeline. Given the number of hits, this library can be panned under normally impossible aggressive conditions, recovering hundreds of picomolar binders, saturating coverage of hits against every epitope, and isolating multi-species cross-reactive members against target homologs without additional engineering.

  • Pre-optimize hits now to save time and reduce costs later

    While the CDR-H3 and the V-gene frameworks define much of a clone’s interaction with target, variations in the other CDRs can impact affinity and breadth of reactivity. The human antibody library was designed with about 5 billion CDR-H3s but 76 billion total antibodies. Due to the combinatorial design, each hit from the antibody library screening will appear with multiple variants. The result is key engineering guidance and optimization of every hit right out of the library.

Compile, analyze and optimize antibodies

Artificial-intelligence based Tumbler technology provides a method for rapidly generating 500+ million versions of an input antibody in order to affinity mature, thermostabilize, deimmunize, species-cross react, biochemical liability remove, humanize, pH sensitize, and otherwise engineer an input antibody.

AbGenesis is a user-friendly cloud-based computational platform that compiles and analyzes sequence data quickly so researchers can quickly complete antibody and immune repertoire analyses. From analyzing individual cells to millions of B-cell and T-cell receptors, as well as linking sequence and phenotype (affinity, expression efficiency, stability) data, AbGenesis allows researchers to derive meaningful insights and make informed decisions on all facets of antibody discovery.

End-to-end Platform for Therapeutic Antibody Discovery and Development

This antibody discovery platform technology with antibody library screening from Distributed Bio together with the extensive capabilities of Charles River creates a unique end-to-end platform for therapeutic antibody discovery programs. Learn more about the integrated target to clinic portfolio:

  • In vivo pharmacology
  • In vitro biology
  • Safety pharmacology
  • Biologics testing solutions
  • Antibody production

Contact an Antibody Library Screening Specialist


Charles River offers antibody development services using the SuperHuman antibody screening library, offering developability, diversity, and fully human VHH antibodies. In 1986 the US FDA approved the first mAb to limit organ transplant rejection. Follow the journey, where next generation antibody discovery technologies contribute to therapeutic or diagnostic mAbs now approved. Read the article


Antibody Library Screening Frequently Asked Questions (FAQs):

  • What is the SuperHuman antibody library?

    The SuperHuman antibody screening library, delivered by Distributed Bio and made commercially available by Charles River, is an antibody screening library that was computationally optimized for both sequence diversity and engineering fitness. Through the analysis of human antibody repertoires and known monoclonal therapeutics in human phase trials, it delivers thousands of unique hits with superior affinity, cross-species coverage, and improved drug-like characteristics in as little as four weeks. Interested in learning more? Consult a Charles River antibody discovery specialist.

  • Why is specificity important in antibody discovery?

    Specificity, or dangerous and problematic off-target effects against a different gene product than the intended target, is particularly problematic for CAR-T and pMHC-targeting antibodies. The SuperHuman antibody library screening technology addresses specificity in three ways. It:

    • Incorporates an immense library with up-front deselection against other off-targets
    • Builds the library from fully human complementarity-determining regions (CDRs) that have already been pre-filtered by the human body
    • Uses high throughput sequencing of hundreds of millions of antibody reads from multiple panning programs, ensuring antibodies against a given target have not enriched against any other target

    To learn more about specificity, read Identifying specificity groups in the T cell receptor repertoire, published in Nature 21 June 2017.

  • Does this antibody library have success with challenging target classes such as GPCRs?

    Clients often partner with Charles River on challenging targets. For antibody hit discovery programs against difficult targets such as G-protein-coupled receptors GPCRs, anti-idiotype antibodies, pMHC-complex targeting antibodies, and challenging epitopes on targets like PD1, Charles River can help. This antibody discovery platform successfully generated hits against the class A GPCR CXCR5 and has optimized hits against another (undisclosed) GPCR. There is no longer a need to go to non-human antibodies to target GPCRs. Beyond target discovery, Charles River can help with pharmacology studies, regulatory safety support and all the way through to IND.

  • How does SuperHuman antibody library screening avoid immunogenicity liabilities?

    Immunogenicity doesn’t manifest itself until human trials. Liabilities can surface at this late stage and the therapeutic can be rendered inactive and even cause negative health outcomes in recipients. The SuperHuman antibody library addresses immunogenicity up front by using antibodies that look entirely human by design. It includes antibodies with no mutations in the frameworks. This phage display antibody library includes only frameworks with dominant alleles found in all human populations in addition to CDR diversity that contains only the variations that the human body is able to produce.